Top Story

AUGMENT-HF: Novel implantable device safe, effective in patients with advanced HF

November 26, 2014

CHICAGO — A novel implantable device was administered safely and associated with clinical benefit in patients with advanced HF, according to phase 2 trial data presented at the American Heart Association Scientific Sessions.

Researchers studied the safety and efficacy of an alginate hydrogel (Algisyl-LVR, LoneStar Heart Inc.) that is injected into the midwall of the left ventricle of patients with dilated LV, where it remains as a permanent implant intended to reduce LV wall stress and prevent or reverse the progression of HF.

thumbnail for video 3909640743001 Meeting News CoverageVideo

VIDEO: Increased infective endocarditis incidence in England may merit re-evaluation of treatment guidelines

November 25, 2014
CHICAGO — In this video, John G. Harold, MD, cardiologist at the Cedars-Sinai Heart Institute, discusses data presented at the American Heart Association…
In the Journals

PROTECTION AMI: Cardiac troponin I levels predicted STEMI outcomes

November 25, 2014
In a new analysis, researchers reported an independent association between measurement of cardiac troponin I levels after primary PCI for STEMI and clinical outcomes and…
In the Journals

Beta-blockers lowered all-cause mortality in patients with HFpEF

November 25, 2014
Patients with HF with preserved ejection fraction who received treatment with beta-blockers had lower rates of all-cause mortality, according to new study…
Dion Stub, MD, PhD Meeting News CoveragePerspective

Supplemental oxygen increased myocardial injury, infarct size in patients with STEMI

November 25, 2014
CHICAGO — Patients with STEMI and normal oxygen levels who received supplemental oxygen before and during hospitalization exhibited signs of increased myocardial…
More News Headlines »
Controversial Issues and Challenging Cases

Controversial Issues and Challenging Cases in the New Frontier of Obesity Online Activity

This activity is supported by an educational grant from Eisai Inc.

Obesity has become a world-wide issue of utmost importance as its incidence and prevalence are associated with dramatic…
More »
Meeting News Coverage Video
thumbnail for video 3907832195001

Anna Axelsson, MD: Results from INHERIT do not 'close the door' on losartan

November 24, 2014
CHICAGO — While results from the INHERIT trial indicate that losartan had no effect on left ventricular mass or…
More »
Risk Management in the Cardiovascular Disease Arena

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »